{"id":5091,"date":"2024-01-04T11:32:33","date_gmt":"2024-01-04T10:32:33","guid":{"rendered":"https:\/\/www.ptc.cz\/sto-lijecimo\/prostata\/jak-poznat-rakovinu-prostaty\/vysledky-prazskeho-protonoveho-centra\/"},"modified":"2024-06-21T14:47:11","modified_gmt":"2024-06-21T12:47:11","slug":"rezultati-praskog-protonske-centra","status":"publish","type":"page","link":"https:\/\/www.ptc.cz\/hr\/sto-lijecimo\/prostata\/rak-prostate\/rezultati-praskog-protonske-centra\/","title":{"rendered":"Rezultati Pra\u0161kog Protonske Centra"},"content":{"rendered":"
\n
\n
\n

Dlouhodob\u00e9 v\u00fdsledky l\u00e9\u010dby karcinomu prostaty v Protonov\u00e9m centru v Praze publikovaly dva presti\u017en\u00ed medic\u00ednsk\u00e9 \u010dasopisy.<\/strong><\/p>\n

Ultra-hypofrakcionov\u00e1 protonov\u00e1 radioterapie v\u00a0l\u00e9\u010db\u011b st\u0159edn\u011b a n\u00edzkorizikov\u00fdch n\u00e1dor\u016f prostaty \u2013 v\u00fdsledky za obdob\u00ed 5 let od ukon\u010den\u00ed l\u00e9\u010dby<\/em><\/strong>.<\/em><\/p>\n

Jednou z prvn\u00edch prac\u00ed, kter\u00e1 na z\u00e1klad\u011b dat o l\u00e9\u010db\u011b pacient\u016f v PTC vy\u0161la v polovin\u011b \u00fanora roku 2021.<\/p>\n

Studii publikoval presti\u017en\u00ed zahrani\u010dn\u00ed \u010dasopis pro radia\u010dn\u00ed onkologii International Journal of Radiation Oncology, Biology and Physics a <\/em>\u00a0sledovala v pr\u016fb\u011bhu 8 let celkem 279 pacient\u016f, kte\u0159\u00ed se l\u00e9\u010dili s karcinomem prostaty pomoc\u00ed protonov\u00e9 radioterapie metodou tu\u017ekov\u00e9ho skenov\u00e1n\u00ed (v pr\u016fm\u011bru l\u00e9\u010dba trvala 9 dn\u00ed). P\u0159inesla zaj\u00edmav\u00e9 v\u00fdsledky. \u201eTy ukazuj\u00ed, \u017ee 5 let po l\u00e9\u010db\u011b je 97 % pacient\u016f s n\u00edzce rizikov\u00fdm karcinomem prostaty vyl\u00e9\u010deno a nedo\u0161lo u nich ke zv\u00fd\u0161en\u00ed PSA (neboli prostatick\u00e9ho antigenu). U pacient\u016f s karcinomem prostaty st\u0159edn\u00edho rizika m\u016f\u017eeme konstatovat, \u017ee jich bylo vyl\u00e9\u010deno celkem 90 %,\u201c <\/em>uv\u00e1d\u00ed doc. MUDr. Ji\u0159\u00ed Kube\u0161, Ph.D. Ve\u00a0sledovan\u00e9m souboru pacient\u016f nav\u00edc nikdo z\u00a0pacient\u016f na karcinom prostaty nezem\u0159el a v\u0161ichni pacienti m\u011bli jen minim\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (tzv. toxicitu).<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n

\n
\n

Po publikaci t\u00e9to studie t\u00fdm l\u00e9ka\u0159\u016f Protonov\u00e9ho centra ve sv\u00e9m l\u00e9\u010debn\u00e9m a publika\u010dn\u00edm \u00fasil\u00ed d\u00e1le pokra\u010doval a v\u00fdsledkem je druh\u00e1, retrospektivn\u00ed anal\u00fdza, jej\u00edm\u017e hlavn\u00edm \u00fa\u010delem bylo potvrdit v\u00fdsledky prvn\u00ed studie.<\/p>\n

P\u011btilet\u00e1 anal\u00fdza \u00fa\u010dinnosti a toxicity ultra-hypofrakcionovan\u00e9 protonov\u00e9 radioterapie p\u0159i l\u00e9\u010db\u011b karcinomu prostaty s n\u00edzk\u00fdm a st\u0159edn\u00edm rizikem – retrospektivn\u00ed anal\u00fdza <\/em><\/strong><\/p>\n

Vy\u0161la v roce 2023 v recenzovan\u00e9m l\u00e9ka\u0159sk\u00e9m \u010dasopise Cancers<\/em>. \u201eU\u017e p\u0159ed publikac\u00ed na\u0161\u00ed prvn\u00ed pr\u00e1ce obecn\u011b sch\u00e1zela cenn\u00e1 data z\u00a0l\u00e9\u010dby v\u011bt\u0161\u00edho souboru pacient\u016f. Proto je na\u0161e druh\u00e1 anal\u00fdza jak\u00fdmsi roz\u0161\u00ed\u0159en\u00edm d\u0159\u00edve publikovan\u00fdch v\u00fdsledk\u016f, kter\u00e9 jsme zve\u0159ejnili na z\u00e1klad\u011b pozorov\u00e1n\u00ed men\u0161\u00edho po\u010dtu pacient\u016f. Na\u0161\u00edm c\u00edlem bylo tentokr\u00e1t ov\u011b\u0159it v\u00fdsledky protonov\u00e9 l\u00e9\u010dby u karcinomu prostaty na dostate\u010dn\u011b velk\u00e9m souboru pacient\u016f, kte\u0159\u00ed l\u00e9\u010dbu protony podstoupili<\/em>,\u201c vysv\u011btluje d\u016fvody pro vznik druh\u00e9 anal\u00fdzy docent Kube\u0161.<\/p>\n

B\u011bhem minim\u00e1ln\u00edho 6m\u011bs\u00ed\u010dn\u00edho post oza\u0159ovac\u00edho sledov\u00e1n\u00ed odl\u00e9\u010den\u00ed pacienti podstupovali klinick\u00e1 vy\u0161et\u0159en\u00ed, m\u011b\u0159en\u00ed PSA a vyhodnocov\u00e1n\u00ed p\u0159\u00edpadn\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f l\u00e9\u010dby (tzv. toxicitu). \u201eI v\u00fdsledky druh\u00e9 studie n\u00e1m potvrdily t\u00e9m\u011b\u0159 97% \u00fasp\u011b\u0161nost vyl\u00e9\u010den\u00ed onemocn\u011bn\u00ed u pacient\u016f s\u00a0n\u00edzcerizikov\u00fdm onemocn\u011bn\u00edm. Biochemick\u00fd n\u00e1vrat onemocn\u011bn\u00ed jsme zaznamenali pouze u 58 pacient\u016f, co\u017e p\u0159edstavuje 6,8 % z\u00a0celkov\u00e9ho po\u010dtu 853 sledovan\u00fdch pacient\u016f. 94,1 % pacient\u016f z cel\u00e9ho sledovan\u00e9ho souboru bylo v 5let\u00e9m sledovac\u00edm obdob\u00ed bez biochemick\u00e9 recidivy onemocn\u011bn\u00ed,<\/strong><\/em>\u00a0komentuje z\u00e1v\u011bry potvrzovac\u00ed anal\u00fdzy prim\u00e1\u0159 Kube\u0161.<\/p>\n

\"\"<\/p>\n<\/div>\n<\/div>\n<\/div>\n

Dlouhodob\u00e9 v\u00fdsledky l\u00e9\u010dby karcinomu prostaty v Protonov\u00e9m centru v Praze publikovaly dva presti\u017en\u00ed medic\u00ednsk\u00e9 \u010dasopisy.<\/strong><\/p>\n

Ultra-hypofrakcionov\u00e1 protonov\u00e1 radioterapie v\u00a0l\u00e9\u010db\u011b st\u0159edn\u011b a n\u00edzkorizikov\u00fdch n\u00e1dor\u016f prostaty \u2013 v\u00fdsledky za obdob\u00ed 5 let od ukon\u010den\u00ed l\u00e9\u010dby<\/em><\/strong>.<\/em><\/p>\n

Jednou z prvn\u00edch prac\u00ed, kter\u00e1 na z\u00e1klad\u011b dat o l\u00e9\u010db\u011b pacient\u016f v PTC vy\u0161la v polovin\u011b \u00fanora roku 2021.<\/p>\n

Studii publikoval presti\u017en\u00ed zahrani\u010dn\u00ed \u010dasopis pro radia\u010dn\u00ed onkologii International Journal of Radiation Oncology, Biology and Physics a <\/em>\u00a0sledovala v pr\u016fb\u011bhu 8 let celkem 279 pacient\u016f, kte\u0159\u00ed se l\u00e9\u010dili s karcinomem prostaty pomoc\u00ed protonov\u00e9 radioterapie metodou tu\u017ekov\u00e9ho skenov\u00e1n\u00ed (v pr\u016fm\u011bru l\u00e9\u010dba trvala 9 dn\u00ed). P\u0159inesla zaj\u00edmav\u00e9 v\u00fdsledky. \u201eTy ukazuj\u00ed, \u017ee 5 let po l\u00e9\u010db\u011b je 97 % pacient\u016f s n\u00edzce rizikov\u00fdm karcinomem prostaty vyl\u00e9\u010deno a nedo\u0161lo u nich ke zv\u00fd\u0161en\u00ed PSA (neboli prostatick\u00e9ho antigenu). U pacient\u016f s karcinomem prostaty st\u0159edn\u00edho rizika m\u016f\u017eeme konstatovat, \u017ee jich bylo vyl\u00e9\u010deno celkem 90 %,\u201c <\/em>uv\u00e1d\u00ed doc. MUDr. Ji\u0159\u00ed Kube\u0161, Ph.D. Ve\u00a0sledovan\u00e9m souboru pacient\u016f nav\u00edc nikdo z\u00a0pacient\u016f na karcinom prostaty nezem\u0159el a v\u0161ichni pacienti m\u011bli jen minim\u00e1ln\u00ed ne\u017e\u00e1douc\u00ed \u00fa\u010dinky (tzv. toxicitu).<\/p>\n

 <\/p>\n

Po publikaci t\u00e9to studie t\u00fdm l\u00e9ka\u0159\u016f Protonov\u00e9ho centra ve sv\u00e9m l\u00e9\u010debn\u00e9m a publika\u010dn\u00edm \u00fasil\u00ed d\u00e1le pokra\u010doval a v\u00fdsledkem je druh\u00e1, retrospektivn\u00ed anal\u00fdza, jej\u00edm\u017e hlavn\u00edm \u00fa\u010delem bylo potvrdit v\u00fdsledky prvn\u00ed studie.<\/p>\n

P\u011btilet\u00e1 anal\u00fdza \u00fa\u010dinnosti a toxicity ultra-hypofrakcionovan\u00e9 protonov\u00e9 radioterapie p\u0159i l\u00e9\u010db\u011b karcinomu prostaty s n\u00edzk\u00fdm a st\u0159edn\u00edm rizikem – retrospektivn\u00ed anal\u00fdza <\/em><\/strong><\/p>\n

Vy\u0161la v roce 2023 v recenzovan\u00e9m l\u00e9ka\u0159sk\u00e9m \u010dasopise Cancers<\/em>. \u201eU\u017e p\u0159ed publikac\u00ed na\u0161\u00ed prvn\u00ed pr\u00e1ce obecn\u011b sch\u00e1zela cenn\u00e1 data z\u00a0l\u00e9\u010dby v\u011bt\u0161\u00edho souboru pacient\u016f. Proto je na\u0161e druh\u00e1 anal\u00fdza jak\u00fdmsi roz\u0161\u00ed\u0159en\u00edm d\u0159\u00edve publikovan\u00fdch v\u00fdsledk\u016f, kter\u00e9 jsme zve\u0159ejnili na z\u00e1klad\u011b pozorov\u00e1n\u00ed men\u0161\u00edho po\u010dtu pacient\u016f. Na\u0161\u00edm c\u00edlem bylo tentokr\u00e1t ov\u011b\u0159it v\u00fdsledky protonov\u00e9 l\u00e9\u010dby u karcinomu prostaty na dostate\u010dn\u011b velk\u00e9m souboru pacient\u016f, kte\u0159\u00ed l\u00e9\u010dbu protony podstoupili<\/em>,\u201c vysv\u011btluje d\u016fvody pro vznik druh\u00e9 anal\u00fdzy docent Kube\u0161.<\/p>\n

B\u011bhem minim\u00e1ln\u00edho 6m\u011bs\u00ed\u010dn\u00edho post oza\u0159ovac\u00edho sledov\u00e1n\u00ed odl\u00e9\u010den\u00ed pacienti podstupovali klinick\u00e1 vy\u0161et\u0159en\u00ed, m\u011b\u0159en\u00ed PSA a vyhodnocov\u00e1n\u00ed p\u0159\u00edpadn\u00fdch vedlej\u0161\u00edch \u00fa\u010dink\u016f l\u00e9\u010dby (tzv. toxicitu). \u201eI v\u00fdsledky druh\u00e9 studie n\u00e1m potvrdily t\u00e9m\u011b\u0159 97% \u00fasp\u011b\u0161nost vyl\u00e9\u010den\u00ed onemocn\u011bn\u00ed u pacient\u016f s\u00a0n\u00edzcerizikov\u00fdm onemocn\u011bn\u00edm. Biochemick\u00fd n\u00e1vrat onemocn\u011bn\u00ed jsme zaznamenali pouze u 58 pacient\u016f, co\u017e p\u0159edstavuje 6,8 % z\u00a0celkov\u00e9ho po\u010dtu 853 sledovan\u00fdch pacient\u016f. 94,1 % pacient\u016f z cel\u00e9ho sledovan\u00e9ho souboru bylo v 5let\u00e9m sledovac\u00edm obdob\u00ed bez biochemick\u00e9 recidivy onemocn\u011bn\u00ed,<\/strong><\/em>\u00a0komentuje z\u00e1v\u011bry potvrzovac\u00ed anal\u00fdzy prim\u00e1\u0159 Kube\u0161.<\/p>\n","protected":false},"excerpt":{"rendered":"

Dlouhodob\u00e9 v\u00fdsledky l\u00e9\u010dby karcinomu prostaty v Protonov\u00e9m centru v Praze publikovaly dva presti\u017en\u00ed medic\u00ednsk\u00e9 \u010dasopisy. Ultra-hypofrakcionov\u00e1 protonov\u00e1 radioterapie v\u00a0l\u00e9\u010db\u011b st\u0159edn\u011b a n\u00edzkorizikov\u00fdch n\u00e1dor\u016f prostaty \u2013 v\u00fdsledky za obdob\u00ed 5 let od ukon\u010den\u00ed l\u00e9\u010dby. Jednou z prvn\u00edch prac\u00ed, kter\u00e1 na z\u00e1klad\u011b dat o l\u00e9\u010db\u011b pacient\u016f v PTC vy\u0161la v polovin\u011b \u00fanora roku 2021. Studii publikoval presti\u017en\u00ed zahrani\u010dn\u00ed \u010dasopis pro radia\u010dn\u00ed onkologii International Journal of…<\/p>\n","protected":false},"author":1,"featured_media":5093,"parent":5082,"menu_order":483,"comment_status":"closed","ping_status":"closed","template":"template-service-detail-with-sidebar.php","meta":{"footnotes":""},"class_list":["post-5091","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/5091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/comments?post=5091"}],"version-history":[{"count":2,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/5091\/revisions"}],"predecessor-version":[{"id":5137,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/5091\/revisions\/5137"}],"up":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/5082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/media\/5093"}],"wp:attachment":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/media?parent=5091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}